Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

L-carnitine on the Prevention of Renal Scarring in Acute Pyelonephritis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02007889
Recruitment Status : Unknown
Verified December 2013 by Azadeh Eshraghi, Shahid Beheshti University.
Recruitment status was:  Recruiting
First Posted : December 11, 2013
Last Update Posted : December 11, 2013
Sponsor:
Information provided by (Responsible Party):
Azadeh Eshraghi, Shahid Beheshti University

Brief Summary:
Risk factors for parenchymal damage in urinary tract infection are vesicoureteral reflux (VUR),obstructive uropathy,the number of flares of acute pyelonephritis(APN) and delay in treatment of acute infection.The pathogenesis of APN is related to bacterial virulenece,immune response,tissue factors,apoptosis and production of free radicals that lead to fibrosis and renal scarring. Oxidative stress in renal cells may be a critical factor in the pathogenesis of pyelonephritis whereas pharmacological management of the oxidative stress response may provide a therapeutic effect in preventing renal pathologies. Animal model show that L-carnitine alleviated oxidative stress, and acute renal inflammatory injury can be prevented much more effectively by carnitine in addition to conventional antibiotic treatment in pyelonephritis.This study is a simple randomized clinical trial (RCT) evaluating the effect of L-carnitine in addition to antibiotic on preventing renal scaring after acute pyelonephritis in children. Simple non- blind randomized clinical trial on 78 patients in 2 groups (intervention & control) is conducted.Children aged 1 month to 10 years with positive urine culture, clinical findings, and 99mTc-dimercaptosuccinic acid (DMSA) scintigraphy-based evidence in favor of acute pyelonephritis were enrolled into a clinical trial. Patients were excluded if they had neurogenic bladder, systemic hypertension, obstructive uropathy. Patients in Intervention group are administered 50 mg/kg/day carnitine in divided 2-3 times/day (maximum 3 g/day) in addition to antibiotic regimens and patients in control group received antibiotic regimens. Primary outcome is the development of renal scar by doing DMSA renal scan on the 7th day of admission and six months after the intervention and compared between groups and secondary outcome is the incidence and severity of pyelonephritis and response to treatment.

Condition or disease Intervention/treatment Phase
Acute Pyelonephritis(APN) Drug: L-carnitine Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 78 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Prevention
Official Title: The Effect of L-carnitine on the Prevention of Renal Scarring in Children With Acute Pyelonephritis
Study Start Date : November 2013
Estimated Primary Completion Date : August 2014
Estimated Study Completion Date : October 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Scars

Arm Intervention/treatment
Active Comparator: L-carnitine
50 mg/kg/day carnitine in divided 2-3 times/day (maximum 3 g/day) in addition to antibiotic regimens
Drug: L-carnitine
50 mg/kg/day carnitine in divided 2-3 times/day (maximum 3 g/day) in addition to antibiotic regimens

No Intervention: Control
control group received just antibiotic regimens without L-carnitine



Primary Outcome Measures :
  1. Development of renal scar by doing DMSA renal scan [ Time Frame: Seven and six months after the intervention ]

Secondary Outcome Measures :
  1. Severity of pyelonephritis and response to treatment. [ Time Frame: Six month after intervention ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Month to 10 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Children aged 1 month to 10 years with positive urine culture, clinical findings, and 99mTc-dimercaptosuccinic acid (DMSA) scintigraphy-based evidence in favor of acute pyelonephritis

Exclusion Criteria:

  • neurogenic bladder,
  • systemic hypertension,
  • obstructive uropathy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02007889


Contacts
Layout table for location contacts
Contact: Azadeh Eshraghi, Ph.D 009809133152584 aepharm@gmail.com

Locations
Layout table for location information
Iran, Islamic Republic of
Isfahan University of Medical Sciences,Alzahra Hospital Recruiting
Isfahan, Iran, Islamic Republic of, 0098
Contact: Azadeh Eshraghi, Ph.D    009809133152584    aepharm@gmail.com   
Sponsors and Collaborators
Shahid Beheshti University
Investigators
Layout table for investigator information
Principal Investigator: Golnaz Vaseghi, Ph.D pharmacology Physiology Research Center
Principal Investigator: Alaleh Gheisari Pediatric Nephrologist,Isfahan University, Isfahan, Iran
Principal Investigator: Nahid Aslani, Resident of pediatrics Isfahan University of Medical Sciences
Principal Investigator: Azadeh Eshraghi, Clinical Pharmacist Shahid Beheshti University of Medical Sciences
Layout table for additonal information
Responsible Party: Azadeh Eshraghi, Clinical Pharmacist, Shahid Beheshti University
ClinicalTrials.gov Identifier: NCT02007889    
Other Study ID Numbers: ShahidBU
First Posted: December 11, 2013    Key Record Dates
Last Update Posted: December 11, 2013
Last Verified: December 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Pyelonephritis
Nephritis, Interstitial
Nephritis
Kidney Diseases
Urologic Diseases
Pyelitis